Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8537256 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2018 | 67 Pages |
Abstract
Chronic stress is a risk factor for a number of physiological disorders including cardiovascular disease, obesity and gastrointestinal disorders, as well as psychiatric and neurodegenerative disorders. There are a number of underlying molecular and cellular mechanisms altered in the course of chronic stress, which may increase the vulnerability of individuals to develop psychiatric disorders such as depression, and neurodegenerative disorders such as Alzheimer's Disease (AD). This is evident in the influence of stress on large-scale brain networks, including the resting state Default Mode Network (DMN), the effects of stress on neuronal circuitry and architecture, and the cellular and molecular adaptations to stress, which may render individuals with stress related psychiatric disorders more vulnerable to neurodegenerative disease later in life. These alterations include decreased negative feedback inhibition of the hypothalamic pituitary axis (HPA) axis, decreased dendritic arborization and spine density in the prefrontal cortex (PFC) and hippocampus, and the release of proinflammatory cytokines, which may suppress neurogenesis and promote neuronal cell death. Each of these factors are thought to play a role in stress-related psychiatric disease as well as AD, and have been observed in clinical and post-mortem studies of individuals with depression and AD. The goal of the current review is to summarize clinical and preclinical evidence supporting a role for chronic stress as a putative link between neuropsychiatric and neurodegenerative disease. Moreover, we provide a rationale for the importance of taking a medical history of stress-related psychiatric diseases into consideration during clinical trial design, as they may play an important role in the etiology of AD in stratified patient populations.
Keywords
CREBFDG-PET6-OHDAJnkPFCLTCPSSPCCPSDBLAAβ6-HydroxydopamineDOPAERKCRFAPPFSTDMNMMSEMPFCdopamine-β-hydroxylasecdk5DMPFCPKCIPLvmPFCNFTCTFMini Mental State Examdorsal medial prefrontal cortexCRFR1BPSDNPIVitArs-fcMRIPiBDOPSPCUACTHC-terminal fragmentsL-threo-3,4-dihydroxyphenylserineBDNFc-Jun N-terminal kinaseCeAMAPKforced swim testAmyloidinsulin degrading enzymeApoeapolipoprotein Emild cognitive impairmentStressgamma-aminobutyric acidDepressionlong-term depressionElectroencephalogramIDEAlzheimer's diseasephosphorylated tauPost-synaptic densityhippocampal formationfMRIfunctional magnetic resonance imagingPositron emission tomographytyrosine hydroxylaseNeurofibrillary tangleMIRAGEdefault mode networkSenile plaquecorticotropin-releasing factorBehavioral and psychological symptoms of dementiaBrain-derived neurotrophic factorprefrontal cortexposterior cingulate cortexlateral temporal cortexVentral medial prefrontal cortexInferior parietal lobelocus coeruleusPVNCerebrospinal fluidCSFLTDPerceived Stress ScaleHPAmapEEGnorepinephrinecentral nucleus of the amygdalabasolateral nucleus of the amygdalaparaventricular nucleus of the hypothalamusMCIadrenocorticotropic hormonePETNeuropsychiatric Inventorycyclic AMP response element binding proteinmicrotubule associated proteinamyloid precursor proteinProtein kinase Cmitogen activated protein kinaseβ-amyloid peptidesPittsburgh compound BChATcholine acetyltransferaseextracellular signal-regulated kinasecyclin-dependent kinaseGABAGlucocorticoidsCorticotropin-releasing factor receptor 1Adrenergic receptors
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Jennifer A. Ross, Gediminas Gliebus, Elisabeth J. Van Bockstaele,